[O-18] Oral Session 18 ［Japanese］「Neuromuscular junction disorders 2」

[O-18-2] A Phase III clinical trial of amifampridine (3,4-DAP) in Japanese LEMS patients

Masakatsu Motomura¹, Yuki Hatanaka², Madoka Mori-Yoshimura³, Akira Tsujino⁴, Nobuya Fujita⁵, Ichiro Yabe⁶, Yuko Igarashi⁷, Kimiaki Utsugisawa⁸ (1.Medical Engineering Course, Department of Engineering, The Faculty of Engineering, Nagasaki Institute of Applied Science, Japan, 2.Department of Neurology, Teikyo University Hospital, Japan, 3.Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan, 4.Department of Neurology and Strokology, Nagasaki University Hospital, Japan, 5.Department of Neurology, Nagaoka Red Cross Hospital, Japan, 6.Department of Neurology, Hokkaido University Hospital, Japan, 7.DyDo Pharma, Japan, 8.Department of Neurology, Hanamaki General Hospital, Japan)